ELAHERE

This brand name is authorized in United States. It is also authorized in France, Lithuania.

Active ingredients

The drug ELAHERE contains one active pharmaceutical ingredient (API):

1	Mirvetuximab soravtansine UNII 98DE7VN88D - MIRVETUXIMAB SORAVTANSINE
	Mirvetuximab soravtansine is an antibody-drug conjugate. The antibody is an engineered IgG1 directed against folate receptor alpha (FRα). The function of the antibody portion is to bind to FRα expressed on the surface of ovarian cancer cells. DM4 is a microtubule inhibitor attached to the antibody via a cleavable linker. Upon binding to FRα, mirvetuximab soravtansine is internalised followed by intracellular release of DM4 via proteolytic cleavage. DM4 disrupts the microtubule network within the cell, resulting in cell cycle arrest and apoptotic cell death.
	Read more about Mirvetuximab soravtansine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ELAHERE Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)
ELAHERE Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX26		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX26

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FR	Base de données publique des médicaments	65505616
LT	Valstybinė vaistų kontrolės tarnyba	1101750
US	FDA, National Drug Code	72903-853